Delaney E Hart1, Jason C Gallagher2, Laura A Puzniak3, Elizabeth B Hirsch1. 1. University of Minnesota College of Pharmacy, Minneapolis, Minnesota, USA. 2. Temple University School of Pharmacy, Philadelphia, Pennsylvania, USA. 3. Merck & Co., Inc., Kenilworth, New Jersey, USA.
Abstract
BACKGROUND: Real-world data assessing outcomes of immunocompromised patients treated with ceftolozane/tazobactam (C/T) are limited. This study evaluated treatment and clinical outcomes of immunocompromised patients receiving C/T for multidrug-resistant (MDR) Pseudomonas aeruginosa. METHODS: This was a 14-center retrospective cohort study of adult immunocompromised inpatients treated for ≥24 hours with C/T for MDR P. aeruginosa infections. Patients were defined as immunocompromised if they had a history of previous solid organ transplant (SOT), disease that increased susceptibility to infection, or received immunosuppressive therapies. The primary outcomes were all-cause 30-day mortality and clinical cure. RESULTS: Sixty-nine patients were included; 84% received immunosuppressive agents, 68% had a history of SOT, and 29% had diseases increasing susceptibility to infection. The mean patient age was 57 ± 14 years, and the median (interquartile range) patient Acute Physiology and Chronic Health Evaluation II and Charlson Comorbidity Index scores were 18 (13) and 5 (4), respectively, with 46% receiving intensive care unit care at C/T initiation. The most frequent infection sources were respiratory (56%) and wound (11%). All-cause 30-day mortality was 19% (n = 13), with clinical cure achieved in 47 (68%) patients. Clinical cure was numerically higher (75% vs 30%) in pneumonia patients who received 3-g pneumonia regimens vs 1.5-g regimens. CONCLUSIONS: Of 69 immunocompromised patients treated with C/T for MDR P. aeruginosa, clinical cure was achieved in 68% and mortality was 19%, consistent with other reports on a cross-section of patient populations. C/T represents a promising agent for treatment of P. aeruginosa resistant to traditional antipseudomonal agents in this high-risk population.
BACKGROUND: Real-world data assessing outcomes of immunocompromised patients treated with ceftolozane/tazobactam (C/T) are limited. This study evaluated treatment and clinical outcomes of immunocompromised patients receiving C/T for multidrug-resistant (MDR) Pseudomonas aeruginosa. METHODS: This was a 14-center retrospective cohort study of adult immunocompromised inpatients treated for ≥24 hours with C/T for MDR P. aeruginosa infections. Patients were defined as immunocompromised if they had a history of previous solid organ transplant (SOT), disease that increased susceptibility to infection, or received immunosuppressive therapies. The primary outcomes were all-cause 30-day mortality and clinical cure. RESULTS: Sixty-nine patients were included; 84% received immunosuppressive agents, 68% had a history of SOT, and 29% had diseases increasing susceptibility to infection. The mean patient age was 57 ± 14 years, and the median (interquartile range) patient Acute Physiology and Chronic Health Evaluation II and Charlson Comorbidity Index scores were 18 (13) and 5 (4), respectively, with 46% receiving intensive care unit care at C/T initiation. The most frequent infection sources were respiratory (56%) and wound (11%). All-cause 30-day mortality was 19% (n = 13), with clinical cure achieved in 47 (68%) patients. Clinical cure was numerically higher (75% vs 30%) in pneumonia patients who received 3-g pneumonia regimens vs 1.5-g regimens. CONCLUSIONS: Of 69 immunocompromised patients treated with C/T for MDR P. aeruginosa, clinical cure was achieved in 68% and mortality was 19%, consistent with other reports on a cross-section of patient populations. C/T represents a promising agent for treatment of P. aeruginosa resistant to traditional antipseudomonal agents in this high-risk population.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: A-P Magiorakos; A Srinivasan; R B Carey; Y Carmeli; M E Falagas; C G Giske; S Harbarth; J F Hindler; G Kahlmeter; B Olsson-Liljequist; D L Paterson; L B Rice; J Stelling; M J Struelens; A Vatopoulos; J T Weber; D L Monnet Journal: Clin Microbiol Infect Date: 2011-07-27 Impact factor: 8.067
Authors: Manuel Díaz-Cañestro; Leonor Periañez; Xavier Mulet; M Luisa Martin-Pena; Pablo A Fraile-Ribot; Ignacio Ayestarán; Asunción Colomar; Belén Nuñez; Maria Maciá; Andrés Novo; Vicente Torres; Javier Asensio; Carla López-Causapé; Olga Delgado; José Luis Pérez; Javier Murillas; Melchor Riera; Antonio Oliver Journal: Eur J Clin Microbiol Infect Dis Date: 2018-08-23 Impact factor: 3.267
Authors: Jihad S Obeid; Catherine A McGraw; Brenda L Minor; José G Conde; Robert Pawluk; Michael Lin; Janey Wang; Sean R Banks; Sheree A Hemphill; Rob Taylor; Paul A Harris Journal: J Biomed Inform Date: 2012-11-10 Impact factor: 6.317
Authors: Michael A Pfaller; Matteo Bassetti; Leonard R Duncan; Mariana Castanheira Journal: J Antimicrob Chemother Date: 2017-05-01 Impact factor: 5.790
Authors: Stephanie E Giancola; Monica V Mahoney; Tiffany E Bias; Elizabeth B Hirsch Journal: Ther Clin Risk Manag Date: 2016-05-19 Impact factor: 2.423